With the results of the FLOW trial anticipated next year, as well as high rates of obesity and CVD in type 1 diabetes, there remains an unmet need for additional mechanistic and CVD/kidney outcome studies of GLP1-RAs in the population with type 1 diabetes and CKD [50]
About 80% of participants in tirzepatides clinical trial reported a side effect, most often nausea, diarrhea, and constipation, and 4% to 7% of people had to stop taking it due to side effects, compared with about 3% of people taking a placebo
Trials such as TRIUMPH-1 and TRANSCEND-T2D-1 reported strong results in 2026, but the full regulatory review process takes additional time before any drug can be legally prescribed or compounded
Hot flashes have decreased and sleeping better
MMNST, Malignant Melanotic Nerve Sheath Tumor
Modo de uso: En gallos administrar 0.5 ml